. "* 12 +/- 2 L/hr"@en . . . . . . . . "1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid"@en . . . . . . . . . . . . . . . . . . . . "Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment."@en . "approved"@en . . "11.5-15.6 hours (single dose, oral)"@en . "Symptoms of overdose include CNS and gastrointestinal effects such as decreased activity, somnolence, tremor, convulsions, vomiting, and diarrhea. The minimal lethal intravenous dose in mice and rats is 100 mg/kg."@en . . "Moxifloxacin"@en . . . "Moxifloxacin"@en . . . "For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye)."@en . . . "50% bound to serum proteins, independent of drug concentration."@en . . . . . "Take without regard to meals. Drink liberally. Absorption is not affected by lipid-rich meals or yogourt."@en . . . " "@en . . . "investigational"@en . . . . "Enteric bacteria and other eubacteria"@en . . . . . . . . . "* 1.7 to 2.7 L/kg"@en . . . . . "Approximately 45% of an oral or intravenous dose of moxifloxacin is excreted as unchanged drug (~20% in urine and ~25% in feces)."@en . . . " "@en . . . . . . . . . . . . . . . . "The bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division."@en . . . "# Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, Diener-West M, Merz WG, Bishai WR, Sterling TR: Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003 Dec 1;37(11):1448-52. Epub 2003 Nov 4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14614666"@en . . "354812-41-2"@en . . . . "Manne Reddy, Sajja Eswaraiah, Vetukuri Venkata Naga Raju, Rapolu Kumar, Ningam Srinivasreddy, Vedantham Ravindra, \"Crystalline form III of anhydrous moxifloxacin hydrochloride and a process for preparation thereof.\" U.S. Patent US20050137227, issued June 23, 2005."@en . "Well absorbed from the gastrointestinal tract. Absolute oral bioavailability is approximately 90%. Food has little effect on absorption."@en . . . .